益方生物跌2.07%,成交额1.84亿元,主力资金净流出46.73万元

Core Viewpoint - Yifang Bio experienced a stock price decline of 2.07% on December 23, with a current price of 29.38 CNY per share and a total market capitalization of 16.992 billion CNY [1] Group 1: Stock Performance - Yifang Bio's stock has increased by 120.90% year-to-date, with a slight increase of 0.44% over the last five trading days and an 8.41% increase over the last 20 days, but a decline of 12.84% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on October 31, where it recorded a net buy of -392.836 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Yifang Bio reported a revenue of 30.8935 million CNY, representing a year-on-year growth of 61.27%, while the net profit attributable to shareholders was -181 million CNY, showing a year-on-year increase of 40.59% [2] - As of September 30, 2025, the number of shareholders increased by 26.17% to 12,400, while the average circulating shares per person decreased by 17.52% to 33,810 shares [2] Group 3: Shareholder Structure - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 16.2161 million shares, an increase of 8.162 million shares compared to the previous period [2] - New entrants among the top ten circulating shareholders include Ping An Medical Health Mixed A and Yongying Medical Innovation Selected Mixed Initiation A, holding 6.2749 million shares and 7.9219 million shares, respectively [2]